<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244126</url>
  </required_header>
  <id_info>
    <org_study_id>H-21839</org_study_id>
    <nct_id>NCT01244126</nct_id>
  </id_info>
  <brief_title>Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy</brief_title>
  <official_title>Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the difference in effect of three clinically common
      methods of providing pain medication during surgery for ventilating tubes placed for
      recurring ear infections.The methods are fentanyl dripped in the nose, morphine injected in a
      muscle, and morphine injected in a vein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative anxiety will be assessed by the modified Yale Preoperative Anxiety Scale (mYPAS)
      at two points - (1) prior to separating the patient from the caretaker and bringing the
      patient to the operating room and (2) on application of the facemask. In keeping with our
      current standard practice, the child will be brought to the OR without premedication, and
      anesthesia will be induced and maintained by having the child breath sevoflurane titrated up
      to 8 %, nitrous oxide 70 % and oxygen 30 % via a facemask. In keeping with the guidelines of
      the American Society of Anesthesiologists recommendations, standard monitoring of EKG, pulse
      oxymetry, blood pressure and skin temperature will be performed. After a satisfactory level
      of anesthesia has been achieved, intravenous access will be established. All patients will
      receive intranasal, IM and IV medications as assigned by a computer generated random number
      scheme.Group A -Intranasal Fentanyl 2 mcg/kg (0.04 ml/kg), Normal saline placebo IM and IV:
      Group B Intranasal normal saline (0.01 ml/kg) placebo, Morphine 0.1 mg/kg (0.01 ml/kg)IM and
      IV normal saline placebo (0.01 ml/kg); Group C- Intranasal Placebo - normal saline 0.04
      ml/kg, IM normal saline Placebo 0.01 ml/kg and Morphine 0.1 mg/kg (0.01 ml/kg) IV.

      The surgeon will be asked to describe the condition of the middle ear (worst side) on a scale
      of 1-4 as described by Davis et al. (1 = no fluid; 2 = serous fluid; 3 = pus; and 4 = thick
      tenacious mucus-glue ear). The surgeon will also report any laceration of the ear canal.

      Induction time, surgery start and end time and arrival in PACU time will be recorded. In the
      postoperative care unit the pain score will be measured by the FLACC's pain scale (Face,
      Legs, Activity, Cry, Consolability), adverse emergence behavior will be measured by PAED
      scale described by Sikich et. al. (Pediatric Anesthesia Emergence Delirium Scale). Patients
      with pain scores greater than 4 will receive morphine 0.05 mg/kg IV, to be repeated once if
      the pain score remains greater than 4 after 10 minutes. Acetaminophen 10-15 mg/kg will be
      administered enterally for pain scores between 1-3.

      The incidence of oxygen desaturation (pulse oximetry values less than 95% for greater than 30
      secs), emesis and need for pain rescue medication will be recorded. The times of arrival in
      PACU, eye opening, response to command, ambulation, discharge readiness, and actual discharge
      home will be recorded as well. Parental satisfaction with postoperative pain control and the
      overall experience will be measured on a 10-point (0= completely dissatisfied -10= completely
      satisfied) verbal rating scale. A postoperative survey will be conducted over the phone the
      following day. Time and dose of postoperative medications, quality and duration of sleep,
      appetite and incidence of nausea and vomiting, time patient returned to presurgical level of
      playing and normal behavior and parent satisfaction will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Postoperative Face, Legs, Activity, Cry and Consolability (FLACC) Pain Score.</measure>
    <time_frame>Upon arrival in the PACU, and at 5, 10, 15, 30, 45, 60 minutes and at discharge</time_frame>
    <description>FLACC assigns 0-2 points for each of 5 categories (face, legs, activity, cry, consolability)and sums these points to give a total score where high scores indicate worse pain (Paediatr Anaesth 2006; 16: 258-65)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum PAED Score</measure>
    <time_frame>Upon arrival in the PACU, and at 5, 10, 15, 30, 45, 60 minutes and at discharge</time_frame>
    <description>Maximum score on the Pediatric Anesthesia Emergence delirium scale. This has 5 items ranging from 1-4 and higher scores indicate greater emergence delirium.
1. eye contact with care giver ,score 1-4, purposeful actions 1-4, aware of surrounding 1-4,restless 1-4, inconsolable 1-4, Maximum score 20.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>IM morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg morphine IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg morphine IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl IN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal fentanyl 2 mcg/kg IN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal fentanyl</intervention_name>
    <description>2mcg/kg fentanyl IN</description>
    <arm_group_label>fentanyl IN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine IM</intervention_name>
    <description>0.1 mg/kg morphine IM for postop pain</description>
    <arm_group_label>IM morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV morphine</intervention_name>
    <description>0.1 mg/kg morphine IV</description>
    <arm_group_label>IV morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bilateral myringotomy

        Exclusion Criteria:

          -  ASA greater than 2

          -  history of bleeding disorder/thrombocytopenia

          -  history of allergy to morphine or fentanyl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Karlberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hippard HK, Govindan K, Friedman EM, Sulek M, Giannoni C, Larrier D, Minard CG, Watcha MF. Postoperative analgesic and behavioral effects of intranasal fentanyl, intravenous morphine, and intramuscular morphine in pediatric patients undergoing bilateral myringotomy and placement of ventilating tubes. Anesth Analg. 2012 Aug;115(2):356-63. doi: 10.1213/ANE.0b013e31825afef3. Epub 2012 Jun 5.</citation>
    <PMID>22669347</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <results_first_submitted>August 9, 2013</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Helena Karlberg</investigator_full_name>
    <investigator_title>Associate Professor Department of Pediatrics and Anesthesiology Texas Children's Hospital Baylor College of Medicine</investigator_title>
  </responsible_party>
  <keyword>otitis media</keyword>
  <keyword>recurrent ear infections (otitis media)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children scheduled for bilateral myringotomy and insertion of tubes at TCH from September 2008 to Feb 2011</recruitment_details>
      <pre_assignment_details>1531 children screened, 1143 excluded as not qualifying, 217 declined to participate</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IM Morphine</title>
          <description>0.1 mg/kg morphine IM</description>
        </group>
        <group group_id="P2">
          <title>IV Morphine</title>
          <description>0.1 mg/kg morphine IV</description>
        </group>
        <group group_id="P3">
          <title>Fentanyl IN</title>
          <description>Intranasal fentanyl 2 mcg/kg IN</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IM Morphine</title>
          <description>0.1 mg/kg morphine IM</description>
        </group>
        <group group_id="B2">
          <title>IV Morphine</title>
          <description>0.1 mg/kg morphine IV</description>
        </group>
        <group group_id="B3">
          <title>Fentanyl IN</title>
          <description>Intranasal fentanyl 2 mcg/kg IN</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Limited to patients who completed study</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="1.6"/>
                    <measurement group_id="B2" value="2.7" spread="2.2"/>
                    <measurement group_id="B3" value="2.4" spread="1.7"/>
                    <measurement group_id="B4" value="2.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight in Kgs</title>
          <description>Excluded 15 patients for protocol violations. These 15 patients did not undergo study procedures Baseline measures only of completed cases</description>
          <units>Kgs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="7.3"/>
                    <measurement group_id="B2" value="15.2" spread="8.1"/>
                    <measurement group_id="B3" value="13.3" spread="4.6"/>
                    <measurement group_id="B4" value="14.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number completing study</title>
          <description>15 cases excluded for protocol violations including 3, 3 and 9 in the IM morphine, IV morphine and IN fentanyl groups respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender in patients completing study</title>
          <description>Excluding protocol violations</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Physical Status in Patients who completed study</title>
          <description>Limited to those who completed study and excluding protocol violations
ASA PHYSICAL STATUS CLASSIFICATION SYSTEM Last approved by the ASA House of Delegates on October 15, 2014 Definition ASA I A normal healthy patient Healthy, non-smoking, no or minimal alcohol use ASA II A patient with mild systemic disease Mild diseases only without substantive functional limitations.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASA Physical Status 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA Physical Status 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Postoperative Face, Legs, Activity, Cry and Consolability (FLACC) Pain Score.</title>
        <description>FLACC assigns 0-2 points for each of 5 categories (face, legs, activity, cry, consolability)and sums these points to give a total score where high scores indicate worse pain (Paediatr Anaesth 2006; 16: 258-65)</description>
        <time_frame>Upon arrival in the PACU, and at 5, 10, 15, 30, 45, 60 minutes and at discharge</time_frame>
        <population>Analysis was performed on per protocol basis excluding patients with protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>IM Morphine</title>
            <description>0.1 mg/kg morphine IM</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>0.1 mg/kg morphine IV</description>
          </group>
          <group group_id="O3">
            <title>Fentanyl IN</title>
            <description>Intranasal fentanyl 2 mcg/kg IN</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Postoperative Face, Legs, Activity, Cry and Consolability (FLACC) Pain Score.</title>
          <description>FLACC assigns 0-2 points for each of 5 categories (face, legs, activity, cry, consolability)and sums these points to give a total score where high scores indicate worse pain (Paediatr Anaesth 2006; 16: 258-65)</description>
          <population>Analysis was performed on per protocol basis excluding patients with protocol violations</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.0"/>
                    <measurement group_id="O2" value="2.7" spread="3.2"/>
                    <measurement group_id="O3" value="2.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary outcome of the study was the maximum postoperative FLACC pain score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Kruskall Wallis ANOVA by ranks</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum PAED Score</title>
        <description>Maximum score on the Pediatric Anesthesia Emergence delirium scale. This has 5 items ranging from 1-4 and higher scores indicate greater emergence delirium.
1. eye contact with care giver ,score 1-4, purposeful actions 1-4, aware of surrounding 1-4,restless 1-4, inconsolable 1-4, Maximum score 20.</description>
        <time_frame>Upon arrival in the PACU, and at 5, 10, 15, 30, 45, 60 minutes and at discharge</time_frame>
        <population>The sample size was based on the assumption that the pain scores in the intranasal fentanyl group would be similar to those in previously published data</population>
        <group_list>
          <group group_id="O1">
            <title>IM Morphine</title>
            <description>0.1 mg/kg morphine IM</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>0.1 mg/kg morphine IV</description>
          </group>
          <group group_id="O3">
            <title>Fentanyl IN</title>
            <description>Intranasal fentanyl 2 mcg/kg IN</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum PAED Score</title>
          <description>Maximum score on the Pediatric Anesthesia Emergence delirium scale. This has 5 items ranging from 1-4 and higher scores indicate greater emergence delirium.
1. eye contact with care giver ,score 1-4, purposeful actions 1-4, aware of surrounding 1-4,restless 1-4, inconsolable 1-4, Maximum score 20.</description>
          <population>The sample size was based on the assumption that the pain scores in the intranasal fentanyl group would be similar to those in previously published data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="6.2"/>
                    <measurement group_id="O2" value="6.3" spread="6.7"/>
                    <measurement group_id="O3" value="4.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskall Wallis test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Kruskall Wallis ANOVA</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IM Morphine</title>
          <description>0.1 mg/kg morphine IM</description>
        </group>
        <group group_id="E2">
          <title>Fentanyl IN</title>
          <description>Intranasal fentanyl 2 mcg/kg IN</description>
        </group>
        <group group_id="E3">
          <title>IV Morphine</title>
          <description>0.1 mg/kg morphine IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study used an objective pain scale where the minimum clinically important difference in scores is unknown. The study did not use a group receiving no active treatment as this was unethical. We also did not measure blood levels of opioids.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Helena Karlberg Hippard</name_or_title>
      <organization>Baylor College of Medicine, Department of Anesthesiology</organization>
      <phone>832-824-5800</phone>
      <email>hxkarlbe@texaschildrens.org; karlberg@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

